Novartis | NVS - Debt


Novartis reported $47B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bausch Health Companies USD 20.78B 16M Jun/2026
Biogen USD 8.09B 1.53B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Canopy Growth CAD 278.71M 19.38M Mar/2026
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Drreddys Laboratories INR 77.34B 9.61B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Merck USD 49.12B 222M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.63B 7.7M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.05B 33.86M Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
Sanofi EUR 20.02B 1.73B Mar/2026
Supernus Pharmaceuticals USD 40.9M 74K Mar/2026
Zoetis USD 9.24B 0 Mar/2026